Insulin glulisine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Insulin glulisine
Clinical data
Trade names Apidra
AHFS/ Monograph
MedlinePlus a607033
License data
  • US: C (Risk not ruled out)
Routes of
ATC code
Legal status
Legal status
CAS Number
  • none
Chemical and physical data
Formula C258H384N64O78S6
Molar mass 5823 g/mol
 ☒N☑Y (what is this?)  (verify)

Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[1] It was developed by Sanofi-Aventis and is sold under the trade name Apidra.[2] When injected subcutaneously, it appears in the blood earlier than human insulin.[3] When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.[4] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.[5]


  1. ^ DailyMed: apidra (insulin glulisine) injection, solution
  2. ^ Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4. 
  3. ^ Garnock-Jones, K. P.; Plosker, G. L. (2009). "Insulin Glulisine". Drugs. 69 (8): 1035–1057. doi:10.2165/00003495-200969080-00006. PMID 19496630. 
  4. ^ Insulin Glulisine
  5. ^ "Sanofi Prescription Products" (PDF). Sanofi. Retrieved 21 April 2012.  |first1= missing |last1= in Authors list (help)

External links[edit]